Table 1.
Group | Animal | Age | Sub-group | No. | PZH * | Ligation | Assay | Remark |
---|---|---|---|---|---|---|---|---|
1 | SHR | 3 m | 1A | 15 | Yes | Yes | I | The ischemia with PZH treatment group |
1B | 15 | Yes | Yes | P | The ischemia with PZH treatment group | |||
2 | SHR | 3 m | 2A | 10 | No | Yes | I | The ischemia group, control for 1A |
2B | 10 | No | Yes | P | The ischemia group, control for 1B | |||
3 | SHR | 3 m | 3A | 6 | Yes | Yes | C | The ischemia with PZH treatment group |
3B | 6 | No | Yes | C | The ischemia group, control for 3A | |||
3C | 6 | No | Sham | C | The sham operation group, control for 3B | |||
4 | WKY | 3 m | 4A | 6 | Yes | Yes | C | The ischemia with PZH treatment group |
4B | 6 | No | Yes | C | The ischemia group, control for 4A | |||
4C | 6 | No | Sham | C | The sham operation group, control for 4B | |||
5 | SHRsp | 7 w | 5A | 17 | Yes # | NA | C | Preventive effects of PZH in stroke |
5B | 17 | No | NA | C | Control group for 5A |
m: month
w: week
I: immunostaining
P: Proteomic
C: Cell death detected by ELISA
* PZH was given for 3 months before the time of ligation, except for Group 5.
# For Group 5A, PZH was given until the brain stroke occurred.